---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-24-000074"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:55:58.071436+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Elicio Therapeutics Q3 2024 net loss $18.8M, cash $26M; AMPLIFY-7P enrollment on track

## Summary
- Net loss $18.8M ($1.39 per share) vs $10.7M ($1.27) YoY; includes $8.5M non-cash warrant liability change.
- Cash and cash equivalents $26.0M as of Sept 30, 2024; operational changes expected to fund into Q2 2025.
- AMPLIFY-7P Phase 2 randomized study enrollment completion expected Q4 2024; interim DFS analysis H1 2025.
- SITC poster showed durable T cell responses and antigen spreading in KRAS mutant tumors; ESMO oral presentation in Dec 2024.
- R&D expense $7.2M, G&A $3.1M; $1.5M grant and $20M convertible notes closed in Q3.

## SEC filing metadata
- accession: 0001601485-24-000074
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000074/0001601485-24-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000074/angn-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-24-000074
- JSON: https://secwatch.observer/filing/0001601485-24-000074.json
- Plain text: https://secwatch.observer/filing/0001601485-24-000074.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.